Cardiac and hematologic responses and survival in AL patients. (A) Survival according to “cardiac stage” in 242 patients with cardiac AL. Thresholds for cTnT and NT-proBNP are > 0.035 μg/L and > 332 ng/L. (Reprinted with permission from Dispenzieri et al., 2004¹²  © 2008 American Society of Clinical Oncology. All rights reserved.) (B, C) NT-proBNP response and progression criteria. Annotated data on 685 AL patients from six countries were pooled and analyzed in order to define and validate cardiac biomarker criteria.¹⁴  (D) Updated event-free survival in the landmark analysis of the phase III MDex vs. SCT trial.²⁴  Eleven patients in the MDex arm (eight in continuous CR) and five patients in the SCT arm (three in continuous CR) have yet to receive second-line therapy. Initially there were 50 patients in each arm. (Courtesy of Dr. Arnaud Jaccard and co-investigators.) (E) Hematologic response criteria and survival. Patients in the international case series were analyzed for survival after therapy based on modified metrics for hematologic response¹³ ; 43.6% received MDex, 11.4% SCT, 22% IMiD-based therapy and only 3% bortezomib and dexamethasone. Response criteria were: CR (immunofixation negative and FLC normal), VGPR (very good partial; reduction in the dFLC to < 40 mg/L), PR (partial; reduction in the dFLC by > 50%), and NR (no response; less than PR). (Courtesy of Dr. Giovanni Palladini and co-investigators.)